AptarGroup (NYSE:ATR) 2025 Earnings Call Presentation

Financial Performance & Targets - Aptar reported FY 2024 sales of $3.6 billion[12], with Pharma contributing 46%, Beauty 34%, and Closures 20%[12] - Adjusted EBITDA for FY 2024 was $775 million[12], with Pharma accounting for 67%, Beauty 19%, and Closures 14%[12] - The company targets long-term core sales growth of 4-7% and an adjusted EBITDA margin of 21-23%[45] - Aptar Pharma targets core sales growth of 7-11% and an adjusted EBITDA margin of 32-36%[45] - Aptar Beauty targets core sales growth of 3-6% and an adjusted EBITDA margin of 15-17%[45] - Aptar Closures targets core sales growth of 4-7% and an adjusted EBITDA margin of 16-18%[45] Strategic Growth Drivers - Pharma's pipeline is expected to add 7-10% annual revenue, with approximately 90% of revenue being repeat business[43, 135] - The company returned $210 million to shareholders through dividends and share repurchases in the first half of 2025[37, 101] - Capital expenditure investments in Pharma represented 54% of the total, while Beauty and Closures accounted for 46% in 2024[96] Market Trends & Innovation - The obesity market is expected to grow at a 23-26% CAGR between 2024-2029[59] - 90% of consumers are more likely to buy brands with sustainable packaging[67]